ACR317 / Adcoris - LARVOL DELTA

ACR317, a novel CDH17-ADC, shows potent efficacy in preclinical gastrointestinal cancer models (AACR 2026) - "The landscape is largely dominated by DS-8201, with many other candidates failing due to efficacy or safety concerns. ACR317 is a novel, highly specific CDH17-targeting ADC. The compelling preclinical efficacy observed suggest its therapeutic potential and form a solid foundation for subsequent clinical investigation in CDH17-positive gastrointestinal cancers."

ADC • Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17